Form 4: Oncology Institute CEO Daniel Virnich Sells Shares to Cover Tax Obligations

Daniel Virnich, CEO of Oncology Institute, sold 10,261 shares of common stock on March 19, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 19, 2025, Daniel Virnich, the CEO of Oncology Institute, sold 10,261 shares of the company's common stock.
• The sale was executed at a price of $0.889 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following the transaction, Virnich still beneficially owns 701,723 shares of Oncology Institute's common stock.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to a stock sale for tax purposes. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives. This transaction does not necessarily indicate a change in the executive's confidence in the company's future prospects.

Comparison to Industry Standards

• Sell-to-cover transactions are standard practice across publicly traded companies, including those in the oncology sector.
• Similar transactions are regularly reported by executives at companies like Amgen, Gilead Sciences, and Bristol Myers Squibb when RSUs vest.

Stakeholder Impact

• The sale of shares by the CEO could have a minor dilutive effect on existing shareholders.
• However, the impact is likely minimal given the relatively small number of shares sold compared to the total outstanding shares.

Key Dates

Keywords

Oncology Institute, Daniel Virnich, TOI, Form 4, SEC Filing, Stock Sale, RSUs, Tax Withholding